NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04513522 2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4 Completed
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT02118337 2021-06-01
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
MedImmune LLC
Phase 1/2 Completed
NCT03065179 2021-03-30
RADVAX
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT03444766 2020-12-04
Study of Nivolumab for Advanced Cancers in India
Bristol-Myers Squibb
Phase 4 Completed
NCT00441337 2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1 Completed